Physician profile
Trish Tran
NPI 1598351033
$14,616.60
in general payments reported to CMS, 2019-2025
25 companies · $5,669 in 2025
The $5,669 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $291 · 2022: $194 · 2023: $3,582 · 2024: $4,881 · 2025: $5,669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,007.53 |
| Education | $123.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,903.60 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $1,502.15 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $1,466.96 | 2021-2025 | Ingrezza |
| Lundbeck LLC | $1,272.40 | 2021-2025 | Rexulti |
| Abbvie INC. | $1,130.69 | 2021-2025 | |
| Alkermes, INC. | $1,078.14 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $988.90 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $896.79 | 2022-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Axsome Therapeutics, INC. | $831.92 | 2023-2025 | Auvelity |
| Corium, LLC | $637.34 | 2023-2025 | Azstarys |
| Almatica Pharma LLC | $577.98 | 2023-2025 | Loreev Xr, Sertraline Hcl, Citalopram |
| Takeda Pharmaceuticals U.S.A., INC. | $547.00 | 2023-2025 | Trintellix |
| Indivior INC. | $506.86 | 2021-2025 | Sublocade, Perseris |
| Vanda Pharmaceuticals INC. | $412.97 | 2023-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $321.01 | 2024-2025 | Cobenfy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $199.49 | 2023-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $79.96 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $73.22 | 2023-2024 | Quviviq |
| Biogen, INC. | $56.70 | 2025 | Zurzuvae |
| Noven Therapeutics, LLC | $38.71 | 2024 | Xelstrym |
| Bausch Health US, LLC | $34.41 | 2025 | Aplenzin |
| Eisai INC. | $18.79 | 2021 | |
| Merck Sharp & Dohme LLC | $17.15 | 2021 | |
| Neos Therapeutics, LP | $15.66 | 2025 | Adzenys Xr-Odt |
| Brainsway USA INC | $7.80 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trish Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.